Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2015-06-04 Regulatory Filings
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobis samarbetspartner Biogen ansöker om marknadsgodkännande för Alprolix® (rFIXFc) i Europa
Regulatory Filings Classification · 95% confidence The document is a press release dated June 4, 2015, from Swedish Orphan Biovitrum AB (Sobi) announcing that its partner, Biogen, has submitted a marketing authorization application for Alprolix (rFIXFc) to the European Medicines Agency (EMA). This announcement concerns a specific corporate event related to regulatory submissions and partnership agreements in the pharmaceutical sector. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement regarding a regulatory step (application submission) that doesn't fit the defined categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), it falls best under the general 'Regulatory Filings' category (RNS) as a significant, non-standard corporate announcement, or potentially as a general announcement related to operations. Given the options, RNS serves as the best fit for a specific, non-financial results-driven regulatory update that isn't a formal SEC filing type listed.
2015-06-04 Swedish
Sobi's partner Biogen submits marketing authorisation application for Alprolix® (rFIXFc) in Europe
Regulatory Filings Classification · 90% confidence The document announces that Sobi's partner, Biogen, has submitted a Marketing Authorisation Application (MAA) for Alprolix to the European Medicines Agency (EMA). This is a specific regulatory event concerning a drug application, which is not explicitly covered by the primary definitions like 10-K, ER, or IR. It is an announcement about a regulatory/legal step in product development/approval. Since it relates to a regulatory submission/action, and does not fit well into M&A (TAR), Director's Dealing (DIRS), or a standard Earnings Release (ER), the most appropriate general category for significant, non-financial, non-shareholder-vote regulatory updates that don't fit elsewhere is the general 'Regulatory Filings' (RNS). It is not a legal proceeding (LTR) but a proactive submission for approval.
2015-06-04 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)" which translates to 'Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)'. It details the date, time, location, registration procedures, and the proposed agenda for the meeting. The agenda explicitly includes items typical of an AGM, such as election of the chairman, approval of the annual report (item 7), decisions on profit distribution (item 11), discharge of directors (item 12), determination of board/auditor fees and elections (items 13, 14, 15), and proposals regarding remuneration guidelines (item 16) and incentive programs (item 17). This content is characteristic of a formal notice for an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2015-05-27 Swedish
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)" and details the date, time, location, procedures for participation (including record dates and proxy rules), and the proposed agenda for the meeting. The agenda items cover standard AGM business such as electing the chairman, approving financial statements, discharging directors, determining fees, and voting on remuneration guidelines and incentive programs. This content perfectly matches the definition of materials shared during an Annual General Meeting. Therefore, the filing type is AGM-R.
2015-05-27 English
Sobi publishes its Report for the First Quarter 2015
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Sobi (Swedish Orphan Biovitrum AB) for Q1 2015. It contains detailed financial statements, business reviews, management commentary, and comparative data for the previous year. It is not an announcement of a report (RPA) or a simple earnings release (ER), as it provides substantive financial analysis and data tables. Therefore, it is classified as an Interim/Quarterly Report. Q1 2015
2015-05-06 English
Sobi publicerar sin rapport för första kvartalet 2015
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Sobi (Swedish Orphan Biovitrum AB) for Q1 2015. It contains detailed financial statements, management commentary, operational highlights, and key performance indicators (KPIs). It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). Q1 2015
2015-05-06 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.